JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 1426.36 KRW | 18.69% |
| 2022 | 1267.10 KRW | 2140.09% |
| 2021 | -62.11 KRW | 90.56% |
| 2020 | -657.85 KRW | 39.59% |
| 2019 | -1088.93 KRW | -464.76% |
| 2018 | 298.53 KRW | 556.96% |
| 2017 | -65.33 KRW | 87.33% |
| 2016 | -515.81 KRW | -992.87% |
| 2015 | 57.77 KRW | 135.17% |
| 2014 | -164.26 KRW | -225.03% |
| 2013 | 131.38 KRW | 109.66% |
| 2012 | -1360.42 KRW | -100.14% |
| 2011 | -679.72 KRW | -280.2% |
| 2010 | 377.20 KRW | -48.5% |
| 2009 | 732.43 KRW | 71.17% |
| 2008 | 427.89 KRW | -15.3% |
| 2007 | 505.18 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 815.74 KRW | -21.21% |
| 2024 Q2 | 346.06 KRW | -57.58% |
| 2023 Q3 | -767.96 KRW | -244.63% |
| 2023 Q2 | 531.00 KRW | -15.74% |
| 2023 Q1 | 630.19 KRW | 14.96% |
| 2023 FY | - KRW | 18.69% |
| 2023 Q4 | 1035.40 KRW | 234.82% |
| 2022 Q4 | 548.20 KRW | 49.14% |
| 2022 FY | - KRW | 2140.09% |
| 2022 Q1 | 424.91 KRW | 246.6% |
| 2022 Q2 | 43.55 KRW | -89.75% |
| 2022 Q3 | 367.58 KRW | 744.04% |
| 2021 Q1 | 163.07 KRW | 149.94% |
| 2021 Q2 | -136.68 KRW | -183.82% |
| 2021 Q3 | 206.43 KRW | 251.03% |
| 2021 FY | - KRW | 90.56% |
| 2021 Q4 | -289.85 KRW | -240.41% |
| 2020 Q4 | -326.52 KRW | -374.46% |
| 2020 Q1 | -99.75 KRW | 90.85% |
| 2020 FY | - KRW | 39.59% |
| 2020 Q3 | 118.97 KRW | 134.58% |
| 2020 Q2 | -344.09 KRW | -244.95% |
| 2019 Q1 | -200.80 KRW | 41.96% |
| 2019 FY | - KRW | -464.76% |
| 2019 Q2 | 64.86 KRW | 132.3% |
| 2019 Q4 | -1090.64 KRW | -2331.72% |
| 2019 Q3 | 48.87 KRW | -24.65% |
| 2018 Q4 | -345.95 KRW | -509.46% |
| 2018 Q3 | 84.49 KRW | -74.47% |
| 2018 Q2 | 331.00 KRW | 88.11% |
| 2018 Q1 | 175.96 KRW | 158.69% |
| 2018 FY | - KRW | 556.96% |
| 2017 Q4 | -299.79 KRW | -234.5% |
| 2017 Q3 | 222.89 KRW | 514.29% |
| 2017 Q2 | -53.80 KRW | -290.92% |
| 2017 Q1 | 28.18 KRW | -93.13% |
| 2017 FY | - KRW | 87.33% |
| 2016 Q3 | -207.64 KRW | 70.89% |
| 2016 Q2 | -713.33 KRW | -1410.79% |
| 2016 Q1 | 54.42 KRW | 46.53% |
| 2016 FY | - KRW | -992.87% |
| 2016 Q4 | 410.18 KRW | 297.54% |
| 2015 Q1 | 11.96 KRW | -94.84% |
| 2015 Q4 | 37.14 KRW | -18.28% |
| 2015 Q3 | 45.45 KRW | 371.51% |
| 2015 Q2 | -16.74 KRW | -239.97% |
| 2015 FY | - KRW | 135.17% |
| 2014 FY | - KRW | -225.03% |
| 2014 Q4 | 231.96 KRW | 1354.29% |
| 2014 Q3 | 15.95 KRW | 106.36% |
| 2014 Q2 | -250.60 KRW | -507.41% |
| 2014 Q1 | 61.51 KRW | 923.46% |
| 2013 Q4 | 6.01 KRW | -81.11% |
| 2013 FY | - KRW | 109.66% |
| 2013 Q1 | 39.78 KRW | 106.81% |
| 2013 Q2 | 51.35 KRW | 29.08% |
| 2013 Q3 | 31.82 KRW | -38.03% |
| 2012 Q4 | -584.01 KRW | -368.44% |
| 2012 FY | - KRW | -100.14% |
| 2012 Q3 | -124.67 KRW | 79.84% |
| 2012 Q1 | 15.84 KRW | 102.87% |
| 2012 Q2 | -618.54 KRW | -4004.92% |
| 2011 Q4 | -552.19 KRW | -113.1% |
| 2011 Q2 | 40.02 KRW | -55.79% |
| 2011 Q1 | 90.53 KRW | 169.91% |
| 2011 Q3 | -259.12 KRW | -747.48% |
| 2011 FY | - KRW | -280.2% |
| 2010 Q4 | -129.50 KRW | -351.02% |
| 2010 FY | - KRW | -48.5% |
| 2010 Q1 | 349.65 KRW | 54.37% |
| 2010 Q3 | 51.59 KRW | -42.55% |
| 2010 Q2 | 89.80 KRW | -74.32% |
| 2009 Q2 | 231.88 KRW | -29.78% |
| 2009 Q4 | 226.50 KRW | 469.98% |
| 2009 Q3 | -61.22 KRW | -126.4% |
| 2009 Q1 | 330.20 KRW | 240.04% |
| 2009 FY | - KRW | 71.17% |
| 2008 Q2 | 283.96 KRW | -1.76% |
| 2008 Q3 | 10.21 KRW | -96.4% |
| 2008 FY | - KRW | -15.3% |
| 2008 Q4 | -235.79 KRW | -2409.4% |
| 2008 Q1 | 289.06 KRW | 191.67% |
| 2007 Q4 | -315.34 KRW | -266.01% |
| 2007 Q1 | 364.96 KRW | 0.0% |
| 2007 Q2 | 401.98 KRW | 10.14% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 189.95 KRW | -52.75% |